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Signaling cascades initiated by Wnt lipoglycoproteins and their receptors of the Frizzled family regulate
many aspects of animal development and physiology. Improper activation of this signaling promotes
carcinogenic transformation and metastasis. Development of agents blocking the Wnt-Frizzled
signaling is of prime interest for drug discovery. Despite certain progress no such agents are as yet
brought to the market or even to clinical trials. One reason for these delays might be the use of
suboptimal readout assays. In this article we overview existing and developing assay platforms to screen
for Wnt-Frizzled antagonists. Among those, G protein-activating assays built on the emerging GPCR
properties of Frizzleds are highlighted.
The Wnt family of evolutionary conserved secreted lipoglycopro-
teins has important roles in animal development, physiology, and
pathology [1]. The very name ‘Wnt’ reflects the history of these
proteins, because their first representatives were simultaneously
discovered as the segment polarity gene wingless in Drosophila [2]
and the integration site int-1 of the mouse mammary tumor virus
in rodents [3]. The first identified receptor for Wnts, Frizzled (FZD)
received its name after a mutation in Drosophila resulted in
randomized orientation of hairs and bristles decorating the insect
cuticle. Cloning of the mutated gene revealed that FZD had the
topology characteristic for G protein-coupled receptors (GPCR)
[4], corroborated by similar analysis performed later on mamma-
lian and other animals’ FZD proteins [5–7]. In the present post-
genomic era, Wnt and FZD families of proteins are known to
comprise 19 and 10 homologs in humans, respectively. Their
ligand–receptor interactions initiate an intricate signaling net-
work orchestrating complex processes of tissue formation and
polarization.
Having crucial functions in animal development, the Wnt-FZD
signaling pathways are mostly silent in the adult [1], with phy-
siological and pathological exceptions. The former include the
constant activity of the pathway in synaptic remodeling [8] and its
reactivation in tissue regeneration after injury [9]. Pathological
implications of the Wnt signaling include bone and heart disease
[1,10], and cancer [11,12]. Mutational misactivation of the Wnt
pathway is the main driving force in more than 90% cases of colon
cancer [13], whereas approximately 50% of breast cancer cases are
associated with overactivation of this type of signaling [14],
including the most aggressive and therapeutically intractable
triple-negative breast cancer [15]. Other organs and tissues are
also sensitive to carcinogenic transformation upon improper acti-
vation of the Wnt-FZD signaling. Furthermore, this type of signal-
ing becomes additionally involved at later stages of cancer
progression, such as tumor metastasis [16].
All this underlies an urgent necessity for development of antic-
ancer drugs specifically targeting the Wnt-FZD signaling [11]. In
addition to plain antagonists, other molecules interacting with
FZD (agonists, inverse agonists, allosteric modulators) might be
highly useful; for example FZD agonists are promising in regen-
eration medicine and stem cell culturing. Development of human
and/or humanized monoclonal antibodies against pathway com-
ponents represents another approach to Wnt-directed drug
discovery [11]. Both pharmaceutical industry and academic
laboratories actively seek such agents, and several hit compounds
have been identified [17,18]. However, none of them has so far
been brought to clinical trials (http://clinicaltrials.gov) let alone to
registration. We hypothesize that the reason for these delays could
be the suboptimal read-out assays which are prone to identify
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molecules acting at rather downstream levels of the pathway. Such
limitation reduces the specificity of the resulting hits in respect to
the numerous pathways the Wnt-FZD ligand–receptor pairs can
activate. We propose that establishment of readout platforms
specifically directed at upstream levels of the pathway is crucial
for the successful development of anticancer treatments targeting
the Wnt-FZD signaling. The following sections will overview the
existing and developing platforms, preceded with a brief descrip-
tion of the complex Wnt-FZD pathways relevant for cancer.
Three pathways in Wnt-FZD signaling as different
temporal ‘floors’
The most important, developmentally and medically, type of Wnt
signaling is the b-catenin-dependent pathway [1,13]. It is also the
best-characterized: initiated by interaction of a Wnt with a FZD
and a single-pass transmembrane co-receptor LRP5/6, it leads to
rearrangement of the Axin-based destruction complex of proteins,
including adenomatous polyposis coli (APC), glycogen synthase
3b, and casein kinase I. The job of this complex is to bind and
phosphorylate cytoplasmic b-catenin, targeting it for ubiquitiny-
lation and proteasomal degradation [1]. Inactivation of the
destruction complex in response to the Wnt signal enables accu-
mulation of b-catenin, its translocation to nucleus, and interac-
tion with transcription co-factors such as TCF/LEF. The outcome is
expression of a set of growth-promoting target genes, for example,
c-myc and cycD (http://www.stanford.edu/group/nusselab/cgi-
bin/wnt/target_genes). The basic ability of the Wnt b-catenin
signaling to stimulate cell proliferation underlies its major role
in development in addition to carcinogenesis. Mutations in com-
ponents of the destruction complex APC and to a lesser extent
Axin are the major cause of colon cancer [13]. By contrast, in breast
cancer this signaling mostly becomes overactivated at the level of
Wnt overproduction [14] (as is the case in the historic integration
of the mouse mammary tumor virus in the vicinity of int-1, now
called Wnt1, forcing overproduction of the latter in the mammary
gland [3]).
Another pathway in the family of Wnt-FZD cascades is referred
to as planar cell polarity (PCP) signaling [16,19]. Instead of reg-
ulating transcription, PCP controls cytoskeleton, mediating cell
polarization in response to extracellular cues, providing certain
similarities between PCP and chemotaxis [20]. The key role in
cytoskeleton reorganization is achieved by FZD signaling to small
GTPases of the Rho family [21]. Additionally, a set of proteins
(Flamingo/CELSR, Van Gogh/VANGL, Prickle, and FZD itself)
accumulate on the plasma membrane in a polarized manner which
serves to amplify the initial polarizing information [19]; this
process depends on Rab GTPases controlling receptor endocytosis,
directed transport along microtubules, and recycling [22]. Devel-
opmentally, PCP is manifested in uniform polarization of insect
epithelia and mammalian inner ear stereocilia, and in convergent
extension cellular movements required for vertebrate gastrulation
and neuronal tube closure [19]. In cancer, the PCP pathway is
engaged at late stages of tumor progression rendering cancer cells
motile and thus promoting metastasis [16].
Finally, the Ca2+-pathway in Wnt-FZD signaling has been iden-
tified in several systems [23]. Physiological (and pathophysiologi-
cal) significance of mobilization of intracellular Ca2+ upon Wnt
stimulation remains unclear, although this type of response has
been shown to modulate the b-catenin and PCP pathways [23].
These three pathways are typically viewed as different, and
largely isolated, branches of Wnt-FZD signaling. However, it
becomes increasingly clear that the same Wnt-FZD interaction
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FIGURE 1
‘Floors’ of the Wnt-FZD signaling. A schematic representation of the temporal hierarchy of Wnt signaling events is given. The red band represents the fastest Ca2+-
response; the green highlights the later-occurring endosomal translocation of FZDs to establish the PCP; the blue one is for the slowest b-catenin pathway
represented by b-catenin-dependent transcription. Outcome of the signaling at these three ‘floors’ defines the cell’s response to FZD activation. Abbreviations:
FZD: frizzled; PCP: planar cell polarity.
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can induce several ‘branches’ in the same cell [24]. Furthermore,
it is noteworthy that the three pathways operate at very different
time scales: the Ca2+-response taking seconds to minutes, cytos-
keletal reorganization in PCP – minutes to hours, and b-catenin-
dependent transcription – hours to days after cells’ stimulation
with a Wnt. Thus, we propose that they should not be considered
as parallel branches emanating from an activated FZD protein,
but rather as temporally hierarchical, sequential ‘floors’ of the
cellular response (Fig. 1). The relative importance of each of the
floors of Wnt-FZD signaling is determined by the cellular context
(i.e. presence of co-receptors and downstream effectors in addi-
tion to extracellular pathway modulating molecules such as
sFRP, WIF or Dkk [25]), but also often by the design of the
experiment: if it aims at measuring the cells’ response to Wnts
in the scale of days, faster-happening events such as Ca2+ mobi-
lization and cytoskeletal modulations will be omitted from
analysis, and vice versa. The hierarchical model of Wnt signaling
is supported by the existence of key proteins situated at the top of
signaling hierarchy, jointly used by all three pathways: the FZD
protein itself, its interaction scaffolding protein Dishevelled
(Dvl) [26], and its immediate transducer of the heterotrimeric
G protein family [6].
This concept of temporal floors in Wnt signaling has impor-
tant operational meaning. It implies that, when looking for
inhibitors of the b-catenin Wnt signaling, not only the final
transcriptional activation can be used as the readout, but also
events happening at upper ‘floors’ and faster time scales, such as
rise in intracellular Ca2+. In the following sections we discuss
different platforms existing or being developed in Wnt-FZD-
directed drug discovery.
Assays based on transcriptional readouts
Currently the leadership among the approaches to the Wnt path-
way inhibition belongs to assays based on target gene expression.
They can be applied in different cell lines, including those derived
from tumors, and typically utilize an artificial reporter [luciferase,
green fluorescent protein (GFP)] under the TCF/LEF promoter
control whose transcription is induced by accumulation of b-
catenin [27]. Analysis at this culminating point of signaling has
an advantage of screening for substances affecting the signaling at
any level, including even processing and secretion of the Wnt
protein itself if the reporter cells are also made to produce the
ligand which would activate them in the autocrine manner. Search
for the exact target of the hit compounds represents a certain
challenge in this approach and may lead to identification of
previously unanticipated components of the pathway. A good
example is XAV939 identified in a high-throughput screening
(HTS) by Novartis (http://www.novartis.com) as a potent suppres-
sor of the Wnt b-catenin signaling. This small molecule turns out
to inhibit tankyrase 1 and 2 – poly-ADP-ribosylating enzymes
which unexpectedly stabilize Axin [28]. However, tankyrases have
many intracellular targets which may restrict the potential of
XAV939 in clinical development.
But the fundamental limitation of transcription-based assays for
Wnt signaling is that they tend to identify substances acting at
downstream steps of the pathway (e.g. Axin stability as in the
example above or b-catenin interactions with transcription co-
factors [17,18]). This feature was not immediately evident and does
not appear in transcription-based assays for a related signaling
cascade, the Hedgehog pathway whose high-throughput targeting
identified drugs acting at Smoothened, the receptor protein
related to FZD [29]; the first of these drugs is already on the market
to treat basal cell carcinoma. The underlying reason for this
peculiarity of the Wnt transcription-based assays might be the
presence of multiple FZD types on the surface of cells used in the
assays [30]. Cellular systems where only one FZD isoform would be
expressed are currently lacking.
It is clear that substances targeting more downstream steps of
the pathway have a higher risk for adverse effects. Indeed, they
may affect all the normal cases of engagement of the Wnt signaling
such as synaptic plasticity [8] and tissue regeneration [9]. Further-
more, inhibitors of such druggable targets as tankyrase and b-
catenin may additionally affect telomere function, mitosis, and
cell adhesion [31]. These problems are further aggravated when
inhibitors of downstream components (e.g. preventing b-catenin
interaction with the TCF transcription co-factor [32]), are expli-
citly sought. Finally, looking for suppression of Wnt signaling
using b-catenin-dependent transcription limits the search to the b-
catenin pathway. Nevertheless, cancer cells may also utilize the
PCP and Ca2+ types of Wnt signaling for their survival and growth
[16,33].
Therefore, inhibitors acting on elements in the initiation of the
Wnt pathway are required. They can specifically target cancer cell
types relying on a particular Wnt or FZD, such as in case of the
triple negative breast cancers which are FZD7-dependent [15].
Such isoform-specific antagonists are in a high demand [11].
Thus, assays focusing on the early components of Wnt signaling
are needed. Such assays would be ideal to find hits against breast
cancers and metastasizing tumors dependent on overproduction
of Wnts [14,33]. At the first glance, these assays may in contrast
seem helpless when drugs against cancers induced by mutations
in downstream components of the pathway, such as in colon
cancer, are to be sought [13]. However, even in these cases, a
reinforcement of the signaling by overproduction of Wnts or
FZDs, in addition to underproduction of secreted Wnt antago-
nists, has been reported [13,34,35]. Importantly, blockade of
Wnt-FZD interactions by sFRPs (secreted FZD-related proteins)
or anti-Wnt antibodies is efficient in suppressing Wnt signaling,
slowing down growth of colon cancer cells, and promoting their
apoptosis despite the presence of downstream activating muta-
tions [34,35].
Thus, assays focusing on the upstream events in Wnt-FZD
signaling may be promising in identifying agents acting against
different types of cancer. Such assays and the degree of their
development in application to Wnt antagonist screening are
summarized in Fig. 2.
Ligand interaction assays
The most upstream event in GPCR activation is the ligand–recep-
tor interaction, and ligand binding assays have been widely used in
classical GPCR pharmacology and drug discovery [36]. However,
this approach is very problematic in case of Wnt–FZD interactions.
Indeed, Wnts are lipoglycoproteins of approximately 40 kDa in
size. Their production in bacteria or yeast is impossible despite
years of effort, and even in cultured mammalian cell lines produc-
tion and purification of only some biologically active Wnts out of
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the 19 human members of this family has been successful; the
resulting proteins are costly. An interesting approach to this
problem has been provided by development of Wnt5a- and
Wnt1-mimetic peptides [37,38]. Despite their promise, these pep-
tides recapitulate only a subfraction of biological activities of the
parental Wnts and can hardly be used in screening for FZD
antagonists. In this regard, we consider our attempts to develop,
through directed protein evolution approaches, ‘super’-Wnts –
smaller and easier in production Wnt proteins with the full scope
of biological activity [39]. However, these attempts are in their
infancy, and at current times establishment of HTS platforms to
screen for Wnt-FZD antagonists based on binding assays appears
impractical. An additional problem originates from apparent exis-
tence of several Wnt binding sites on FZD. Indeed, the highly
structured extracellular cysteine-rich domain of FZD is capable of
high-affinity interaction with Wnts [40], but is dispensable for the
biologic activity of FZD [41]. Thus, ligand binding assays might
identify molecules influencing Wnt–FZD interactions, but not
necessarily having a functional consequence to the activation of
Wnt pathways. Also in this regard the functional readouts of Wnt–
FZD binding are required.
Ca2+-related assays
Rise in intracellular [Ca2+] occurs within seconds of GPCR activa-
tion and involves fewer intermediates as compared to a transcrip-
tional response. Ca2+-assays are thus more promising for finding
small molecules that directly affect the Wnt–FZD interaction.
GPCRs best to be screened by Ca2+-methods are coupled to Go
or Gq heterotrimeric G proteins [42], and FZDs fall into this
category [43–45].
The techniques to follow the Ca2+ pathways are well-established
and involve monitoring of the second messenger inositol-1,4,5-
triphosphate (IP3, produced by phospholipase C and activating
calcium-releasing channels of endoplasmic reticulum) or Ca2+ ions
themselves. The former measure displacement from the purified
IP3-receptor of radioactively or fluorescently labeled IP3 by the
messenger produced in response to GPCR activation [42,46]. Alter-
natively, the IP3 metabolite IP1 can be measured instead [47].
To directly monitor intracellular [Ca2+], a large variety of fluor-
escent and luminescent sensors have been developed [48]. Such
measurements are somewhat less robust in comparison to IP3
detection due to a more transient nature of the signal. The choice
between IP3 and the direct Ca
2+ detection is mainly empirical and
Drug Discovery Today  Volume 17, Numbers 23–24 December 2012 REVIEWS
Adenylate cyclase (cAMP)
Homo- and heterodimerization
GTP-binding assays
Transcriptional readout
Internalization/β-arrestin
FRET
BRET
FRET
BRET
FRET
BRET
FLUO
FLUO FP
Luc
+ Heterodimer targeting
5/6
P
R
L
Adenylate
cyclase β-arrestin
β-catenin
TCF
DvI
Gα
Gβγ
Assay reporters
- Luciferase
FRET
BRET
FRET
BRET
FP
FP
Luc
FLUO
- Radioactive label
- FRET or BRET
- Fluorescent protein fag
- Fluorescent substance
Wnt
FZD
+ Cell-free assay
- Physiological role
  for FZDs is not known
+ Well-established
   method
Ca2+/IP3
Endoplasmic reticulum
+ Quick response
+ Quick response
- Other GPCRs may
  interfere
- Expensive setup
- Monitors only 1 branch - Some setups require
  purified components - Target-unspecific
- Integrates many steps
- Time-consuming
- 1 out of 3 branches
+ Well-established
+ Integrates few steps
+ Specificity
+ Specificity
+ Simplicity
+ Versatility
+ Clear fast output
+ Adjustable
+ Specificity
- Only some FZDs
  are involved
C
C
C
C
Drug Discovery Today 
FIGURE 2
Overview of the major features of available Wnt-FZD antagonists screening approaches. The boxes contain brief information about principal advantages and
drawbacks of the methods described in the paper, as well as summarize data about reporters available for them. Abbreviations: BRET: bioluminescence resonance
energy transfer; FRET: fluorescence resonance energy transfer; IP3: inositol-1,4,5-triphosphate.
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depends on the basal levels of these second messengers in a given
cell type. Production of both messengers in response to FZD
activation has been explicitly demonstrated [23,49]. However,
no high-throughput assay for Wnt-FZD antagonist screening by
IP3 or Ca
2+ has been formatted yet.
Adenylyl cyclase assay
Many FZDs are known to activate heterotrimeric G proteins of the
Gi family [50–53] which are capable of inhibiting cAMP-producing
adenylyl cyclase (AC). Furthermore, some FZDs are coupled to the
heterotrimeric Gs protein [50,54–56] which instead activates AC.
Thus it should be possible to design a Wnt-FZD readout assay
monitoring AC activity. While Gs-mediated activation of cAMP
production is readily detectable, Gi-induced inhibition of the
enzyme is often measured on the background of forced AC activa-
tion by forskolin [57].
High-throughput methods to follow AC activity use cAMP ana-
logs and cAMP-specific antibodies, both of which are labeled with
fluorescent groups. Concentration of the complex, reduced upon
production of ‘cold’ cAMP upon stimulation of the GPCR-Gs-AC
cascade, is quantified by fluorescence resonance energy transfer
(FRET) or bioluminescence resonance energy transfer (BRET) [58].
These methods might be used both for isolated membranes and for
cultured cell lines. cAMP measurements in living cells have also
been developed utilizing cAMP-sensitive ion channels. In cells
expressing these channels a production of the cyclic nucleotide
leads to changes in the membrane potential which could be
detected by a voltage-sensing fluorescent dye and quantified with
a microplate reader. This approach has been successfully employed
to screen for GPCR-targeting molecules [59].
High-content screening for Wnt-FZD signaling
The method of high-content screening (HCS) exploits structural
rearrangements of the cell induced by receptor activation [60].
HCS requires automatic confocal or epi-fluorescent microscopes
used to produce a sequence of images of cells cultured in multiwell
plates. FZD-dependent signaling often leads to profound changes
in cellular morphology and redistribution of cellular components,
and thus is in principle amenable to HCS. However, no such
applications have been developed so far.
Among numerous possible HCS assays, the one monitoring FZD
endocytosis appears attractive, along the lines established for
other GPCRs [61]. Indeed, internalization of activated FZD pro-
teins is utilized in different Wnt pathways and involves early
transducers, making it amenable for screening with the focus
on the early signaling events [43,62]. In most cases internalization
of a GPCR leads to attenuation of the signal. Some GPCRs, and
FZDs among them, contradict this rule [22,63] by the use of the
endosomal compartment for prolonged and enhanced signaling
activity. FZD endocytosis in HCS might be monitored using anti-
bodies specific to extracellular parts of the receptor, or alterna-
tively utilizing FZD fusion with a fluorescent tag not interfering
with endocytosis. FZD internalization thus could be readily
employed to screen for antagonists or agonists of the pathway
in a highly biologically relevant setup. This approach has been
applied to screen for compounds inducing FZD1 endocytosis
among FDA-approved drugs, identifying the anthelmintics niclo-
samide as an indirect inhibitor of Wnt3a signaling [64].
GPCR, and FZD internalization is usually mediated by b-arrestin
binding to the intracellular domain of the receptor, which usually
requires prior phosphorylation [62,65]. This phenomenon has
been applied to increase the robustness of the internalization
monitoring by FRET or BRET between tagged GPCRs and b-
arrestin. Such a double-labeling method is widely used in the
GPCR field and could be observed with any convenient donor–
receptor pair [65]. Unusually for GPCRs, the FZD-b-arrestin inter-
action requires the scaffolding phosphoprotein Dvl as an inter-
mediate [66]. The three proteins, in an immediate proximity to
each other, are brought into the endosomal compartment [66,67].
This feature enables application of highly sensitive energy transfer-
based detection methods for HCS. Looking for agents blocking
interaction of specific FZDs with Dvl is another promising
approach [68].
Screenings based on receptor dimerization
Dimer formation by some FZD proteins is necessary for manifesta-
tion of their activity [69]. Because dimerization appears as an
inherent function and hallmark of correct activation of these
FZDs, molecules which affect this phenomenon will be their
effective antagonists. Techniques to measure the dimerization
ratio, similarly to the b-arrestin monitoring, involve FRET or BRET
between complementary fluorescent tags placed on GPCR mole-
cules [70]. This method should also be potent in monitoring
receptor heterodimerization which is not a rare feature in GPCR
biology and may occur with FZD proteins [70]. As an alternative to
the interactions between two FZDs, proximity between FZD and
LRP5/6 can also be monitored.
GTP-binding assays
For GPCRs, the most immediate functional outcome of the inter-
action with ligand is activation of the guanine nucleotide exchange
on the cognate heterotrimeric G protein. As with other GPCRs, FZD
in some contexts can signal in vivo bypassing the G proteins [55].
Despite this, the capacity of FZDs to activate G proteins represents a
powerful resource to design Wnt-FZD screening platforms, espe-
cially in reconstituted systems ([51,52,54,71,72] http://precedings.
nature.com/site/help).
The capability of GPCRs to increase the rate of GTP incorpora-
tion is monitored by replacing GTP with its non-hydrolysable
labeled analogs, choosing from the main two currently available
on the market: the radioactive [35S]GTPgS and the fluorescent
GTP-Eu [73]. The former has been applied since the dawn of G
protein investigations. It represents a robust and well-established
methodology but suffers from the limitations the radioactive label
imposes on high-throughput applications. The relatively novel
GTP-Eu where GTP is modified with a fluorescent europium che-
late has been designed specifically for HTS using GTP-binding
GPCR assays [73]. Thanks to its higher affinity to G proteins
and dramatically better sensitivity, GTP-Eu is superior to other
available fluorescent GTP analogs such as BODIPY-GTPgS [74]. The
superb sensitivity of GTP-Eu originates from the physical nature of
its fluorophore: unlike in typical fluorescence, it emits light with a
delay post-excitation (this phenomenon is known as time-resolved
fluorescence or phosphorescence). This feature leads to a drastic
improvement of the signal-to-noise ratio, making GTP-Eu an
excellent alternative to [35S]GTPgS [75].
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FZDs can be provided by different sources for HTS GTP-binding
assays. Natural FZD-containing plasma membrane preparations
have been used for this purpose, for example, from rat brains
which express FZD1, FZD3, FZD6, FZD7, and FZD9 [50], or from
microglia-derived N13 cell naturally expressing FZD5 and FZD9
[51]. Other cell lines also express endogenous FZDs [30]. Alterna-
tively, cultured cells can be transfected to overexpress the FZD of
choice to prepare membranes enriched in FZD for the assay [50].
Finally, many functional GPCRs have been expressed in bacteria
[76], and FZD proteins followed this route for subsequent utiliza-
tion in the GTP-Eu-binding assay [71,72]. Clearly, heterotrimeric G
proteins (easily purified from porcine brains) have to be added to
the assay in this case [50,71,72].
There are additional promising developments of the FZD-mea-
suring GTP-binding assays which have not been fully exploited
yet. One is related to the possibility of FZD production in cell-free
transcription-translation systems targeting receptors into deter-
gent micelles or liposomes as has been done for several GPCRs [77].
Another relies on FZD-Ga, Wnt-FZD, and even Wnt-FZD-Ga
fusion proteins. GPCR-Ga fusions provide the fixed receptor
and/or effector ratio and have been successfully used in GPCR
assays [78], while creating the active Wnt-FZD fusions omits the
need of purifying Wnt proteins [79], the cumbersome and expen-
sive task.
Overall, GTP-binding assays monitor the earliest events in the
Wnt pathway and their application for HTS of small-molecule
regulators of FZD proteins opens exciting avenues to identify
pathway inhibitors acting at the level of the receptor.
Concluding remarks
The Wnt-FZD signaling pathways have key roles in initiation and
progression of several types of cancer in human patients. Devel-
opment of proper readout assays applicable for HTS of small
molecules acting on Wnt signaling is of prime importance for
anticancer drug discovery. We have overviewed several existing
and developing platforms monitoring Wnt pathway activation.
Although the current HTS efforts are dominated by the usage of
transcription-based assays, it is our conviction that readouts focus-
ing on the more upstream events of the pathway are in urgent
demand. These readouts largely exploit the emerging GPCR prop-
erties of FZD proteins, the feature for the long time undervalued by
Wnt researchers [43]. Embracing FZDs as part of the GPCR super-
family arms the field with the vast inventory of the GPCR-target-
ing drug discovery approaches [42,61]. We think that
development and application of such approaches should boost
the Wnt signaling-directed drug discovery. The new assays will
hopefully let the Wnt investigators catch up with their peers
working on other cancer-related signaling pathways and advance
the anti-Wnt drug discovery efforts to clinical trials. Novel specific
therapies, primarily against colon and breast cancer, will be the
fruit of these efforts.
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